What we all agree on: Early Friday morning, biopharmaceutical company Merck announced that the drug molnupiravir “reduced the risk of hospitalization or death by approximately 50%” for COVID-19 patients in a Phase 3 trial.

The treatment involves taking a pill twice a day for five days. The company’s contract with the US government set the price of a treatment course at $700, or $70 per pill.